Calif. biotech gets $13.5M funding boost

05/7/2013 | American City Business Journals

NGM Biopharmaceuticals secured almost $13.5 million in an equity offering targeted at $50 million, a securities filing showed. Rather than betting on a single drug, NGM is using a basic-science approach to uncover how genes, hormones and receptors regulate diabetes, obesity and other cardiometabolic disorders. The company hopes to develop a treatment that mimics the benefits of gastric bypass surgery, which has been shown to improve type 2 diabetes outcomes even before weight loss begins.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ